期刊文献+

疏肝益肾方对三阴乳腺癌患者免疫功能的影响 被引量:7

Influence of Shugan Yishen Decoction on Immune Function in Patients with Triple-negative Breast Cancer
下载PDF
导出
摘要 目的研究疏肝益肾方对三阴乳腺癌患者免疫功能的影响。方法选取2012年11月—2014年1月在我院治疗三阴乳腺癌的患者42例,随机分为两组,每组21例,对照组给予化疗,治疗组给予疏肝益肾方治疗,观察两组患者治疗后症状的改善情况、患者生活质量及体内自然杀伤细胞变化。结果治疗后患者的生活质量及自然杀伤细胞与治疗前比较均提高,治疗组提高程度优于对照组,差异显著(P<0.05);治疗组治疗后失眠、盗汗、疼痛改善情况相比对照组更明显,差异显著(P<0.05)。结论疏肝益肾方可以缓解三阴乳腺癌患者的症状,提高患者生活质量,增加患者免疫系统功能。 Objective To study the influence Shugan Yishen decoction on immune function in patients with triple-negative breast cancer. Methods 42 cases of patients with triple-negative breast cancer were treated in our hospital from November 2012 to January 2014 were randomly divided into two groups, and each group had 21 cases. The control group was given chemotherapy, and the treatment group was given Shugan Yishen decoction. The improvement of symptoms, the quality of life and the changes of natural killer cells of the two groups were observed. Results Comparing with the control group, the quality of life and natural killer cells in the treatment group were higher than those in the control group, and the difference was significant (P 〈 0. 05). The improvement on insomnia, night sweats and pain relief of the treatment group after treatment was more obviously than the control group, and the difference was significant (P 〈 0. 05). Conclusion Shugan Yishen decoction can alleviate the symptoms of patients with triple negative breast cancer, improve the quality of life of patients, and increase patien's immune system function.
作者 王涛
出处 《光明中医》 2016年第21期3134-3135,共2页 GUANGMING JOURNAL OF CHINESE MEDICINE
关键词 疏肝益肾方 三阴乳腺癌 免疫功能 Shugan Yishen decoction Triple-negative breast cancer Immune function
  • 相关文献

参考文献5

二级参考文献48

  • 1王玲,单保恩,张建彬.塞来昔布对人三阴性乳腺癌细胞MDA-MB-231迁移、侵袭及黏附性的影响[J].中国癌症杂志,2011,21(4):266-271. 被引量:15
  • 2石书芳.陈熠运用调神解郁法治疗乳腺癌术后临床分析[J].四川中医,2013,31(8):12-14. 被引量:3
  • 3林毅,陈前军,刘鹏熙.乳腺癌分期辨证规范化——一个中医乳房病学与时俱进的重要课题[J].中西医结合学报,2006,4(5):447-450. 被引量:35
  • 4Richard D.Blackmore,赵秀明.十月的日出[J].世界文化,2007(3):36-36. 被引量:3
  • 5段富津.方剂学[M].5版.上海:上海科学技术出版社,1997:59.
  • 6方积乾,郝元涛.健康状况调查问卷(SF-36)[J].中国行为医学科学,2001,10(特刊):19-24.
  • 7Prat A,Adamo B,Cheang M C, et al.Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. The Oncologist . 2013
  • 8Elizabeth M.H. Kim,Kelly Mueller,Elaina Gartner,Julie Boerner.Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells[J]. Journal of Surgical Research . 2013
  • 9Cynthia X. Ma,Matthew J. C. Ellis,Gina R. Petroni,Zhanfang Guo,Shi-rong Cai,Christine E. Ryan,A. Craig Lockhart,Michael J. Naughton,Timothy J. Pluard,Christiana M. Brenin,Joel Picus,Allison N. Creekmore,Tibu Mwandoro,Erin R. Yarde,Jerry Reed,Mark Ebbert,Philip S. Bernard,Mark Watson,Laurence A. Doyle,Janet Dancey,Helen Piwnica-Worms,Paula M. Fracasso.A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer[J]. Breast Cancer Research and Treatment . 2013 (2)
  • 10Hsiao-Ching Chuang,Naval Kapuriya,Samuel Kulp,Ching-Shih Chen,Charles Shapiro.Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells[J]. Breast Cancer Research and Treatment . 2012 (2)

共引文献73

同被引文献139

引证文献7

二级引证文献103

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部